Grace Therapeutics
GRCE | NASDAQ
$1.75
-$0.06 (-3.31%)
At close: Nov 16, 2026, 4:00 PM ET
$1.75
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-3.31%
(1D)No price chart data available for 1D timeframe.
Rating
34.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #676/1021 (Top 66%)
Key Statistics
Market Data
Market Cap $35.2M
1D Range
1.73 1.77
52W Range
1.73 5.13
Valuation (TTM)
PE -1.37
PB 0.63
EV/EBITDA -0.57
Valuation (NTM)
Forward PE N/A
Forward PEG 0.08
Price Target $4.00
Cash Flow
FCF Yield -25.4%
SBC Adj. FCF Yield -27.1%
SBC Impact -6.6%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 2.2% |
35.7%
FCF 3Y | 5Y 13.3% |
14.4%
Returns
ROA -38.6%
ROE -38.3%
ROIC -40.5%
Financial Health
Net Cash
$21.31M
Current Ratio 13.61
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The comp...
Sector Healthcare
Industry Biotechnology
Employees 5
IPO Date Feb 7, 2012
Website www.gracetx.com
Fiscal Year April - March
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$4.00
Upside
+128.57%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove GRCE